Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study
China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...
Clinical trial approval / initiation
Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...
Luye Pharma Initiates Phase II Study for LY 03014 in China
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...
Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
Hope Medicine Gains Global Approval for Phase II Trial of HMI-115
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...
Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...
Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study
China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global...
Immorna’s JCXH-221 mRNA Vaccine Cleared by FDA for Phase I/II Study
Immorna (Hangzhou) Biotechnology Co., Ltd has announced that the US FDA has cleared its investigational...
Kanghong Pharma Receives FDA Approval for KH631 Gene Therapy Trial
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approval...
Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug
China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II...
China’s First Gene Therapy for Deafness, RRG-003, Begins Clinical Study
RRG-003, an adeno-associated virus (AAV) gene therapy co-developed by China’s Shanghai Dingxin Gene Technology Co.,...
Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...
Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the...
Mabwell Receives Approval for Clinical Study of 9MW3011 in Polycythemia Vera
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving approval to conduct a...
Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC
China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical...
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...
Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...
Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...